---
schema_version: "secwatch.filing_event.v1"
accession: "0001831283-23-000145"
form_type: "8-K"
ticker: "LIANY"
cik: "0001831283"
company_name: "LianBio"
filed_at: "2023-12-26T23:59:59+00:00"
generated_at: "2026-06-07T07:31:38.529154+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# LianBio sells NBTXR3 rights in Asia to Janssen for $25M upfront plus potential $5M milestone

## Summary
- Asset Purchase Agreement with Janssen (Johnson & Johnson) executed Dec 22, 2023.
- LianBio receives $25 million one-time payment at closing.
- Eligible for $5 million milestone if annual net sales in PRC exceed $20 million.
- Transition activities to be completed within six months post-closing.
- Concurrent Novation Agreement with Nanobiotix consenting to the deal.

## SEC filing metadata
- accession: 0001831283-23-000145
- form_type: 8-K
- ticker: LIANY
- cik: 0001831283
- company_name: LianBio
- filed_at: 2023-12-26T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 1.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1831283/000183128323000145/0001831283-23-000145-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1831283/000183128323000145/lian-20231222.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001831283-23-000145
- JSON: https://secwatch.observer/filing/0001831283-23-000145.json
- Plain text: https://secwatch.observer/filing/0001831283-23-000145.txt

## Key facts
- Material Agreements
  LianBio terminated License, Development and Commercialization Agreement with Nanobiotix S.A..
  - Action: termination
  - Agreement: license
  - Counterparty: Nanobiotix S.A.
  source text: Item 1.02 Termination of a Material Definitive Agreement. The disclosures regarding the Transactions set forth in Item 1.01 above are incorporated by reference into this Item 1.02.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1831283/000183128323000145/0001831283-23-000145-index.htm
- Material Agreements
  LianBio entered into Asset Purchase Agreement with Janssen Pharmaceutica NV valued at $25 million (effective 2023-12-22).
  - Action: entry
  - Agreement: asset purchase
  - Counterparty: Janssen Pharmaceutica NV
  - Value: $25 million
  - Effective: 2023-12-22
  source text: On December 22, 2023 (the “Closing Date”), LianBio Development (HK) Limited (“LianBio Development”), a subsidiary of LianBio, Janssen Pharmaceutica NV (“Janssen”), a Johnson & Johnson company, and, as applicable, LianBio entered into an Asset Purchase Agreement (the “APA”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1831283/000183128323000145/0001831283-23-000145-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.